OC
LAB icon

Oppenheimer & Co’s Standard BioTools LAB Stock Holding History

Oppenheimer & Co’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Sell
326,600
-24,290
-7% -$23K ﹤0.01% 1524
2026
Q1 		$323K Buy
350,890
+231,140
+193% +$280K ﹤0.01% 1358
2025
Q4 		$153K Buy
119,750
+33,150
+38% +$44.5K ﹤0.01% 1470
2025
Q3 		$113K Hold
86,600
– – ﹤0.01% 1605
2025
Q2 		$104K Hold
86,600
– – ﹤0.01% 1561
2025
Q1 		$93.5K Buy
+86,600
New +$122K ﹤0.01% 1521

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Oppenheimer & Co's LAB Position: Q2 2026 in Review

Oppenheimer & Co reduced its Standard BioTools (LAB) stake by 6.9% in Q2 2026, selling an estimated $23K and leaving 326,600 shares worth $269K. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

Oppenheimer & Co first reported a position in LAB in Q1 2025 and has held it in 6 quarters since. The position peaked at $323K in Q1 2026. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Oppenheimer & Co held 326,600 shares of Standard BioTools worth $269K as of Q2 2026.
  • Oppenheimer & Co sold 24,290 Standard BioTools shares in Q2 2026, an estimated $23K.
  • Standard BioTools made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1524 holding.
  • Oppenheimer & Co first reported a position in Standard BioTools in Q1 2025 and has held it in 6 quarters since.
  • Oppenheimer & Co's Standard BioTools position peaked at $323K in Q1 2026.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.